AngioDynamics Inc. (NASDAQ:ANGO) shares were up 1.5% on Wednesday . The stock traded as high as $15.92 and last traded at $15.87, with a volume of 65,365 shares. The stock had previously closed at $15.63.

Separately, Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $14.10.

The company’s market cap is $571.10 million. The company’s 50-day moving average price is $15.54 and its 200 day moving average price is $12.77.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, July 13th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The company earned $93.40 million during the quarter, compared to the consensus estimate of $88.64 million. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.14 earnings per share. On average, equities research analysts expect that AngioDynamics Inc. will post $0.63 earnings per share for the current year.

In other AngioDynamics news, Director David F. Burgstahler sold 2,250,000 shares of AngioDynamics stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the transaction, the director now directly owns 23,988 shares in the company, valued at $350,704.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in AngioDynamics stock. Nationwide Fund Advisors raised its stake in AngioDynamics Inc. (NASDAQ:ANGO) by 252.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,374 shares of the company’s stock after buying an additional 63,332 shares during the period. Nationwide Fund Advisors owned about 0.24% of AngioDynamics worth $1,073,000 as of its most recent SEC filing.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.